70,802 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Bought by Man Group plc

Man Group plc bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 70,802 shares of the company’s stock, valued at approximately $479,000.

Other large investors have also modified their holdings of the company. Private Trust Co. NA purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $27,000. Farther Finance Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after buying an additional 1,353 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Recursion Pharmaceuticals by 43.7% during the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock worth $53,000 after buying an additional 2,387 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in shares of Recursion Pharmaceuticals by 220.7% during the fourth quarter. PNC Financial Services Group Inc. now owns 9,820 shares of the company’s stock worth $66,000 after buying an additional 6,758 shares in the last quarter. Finally, Colonial River Investments LLC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $68,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 1.4%

Shares of RXRX opened at $4.08 on Tuesday. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $3.79 and a 12-month high of $12.36. The firm has a 50-day moving average price of $5.09 and a 200 day moving average price of $6.48. The firm has a market capitalization of $1.66 billion, a P/E ratio of -2.67 and a beta of 0.99.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same period in the prior year, the company posted ($0.39) EPS. The company’s revenue for the quarter was up 7.2% compared to the same quarter last year. Sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Thursday, April 10th. Needham & Company LLC lowered their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, May 6th. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $7.60.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.